Systematic literature review informing the 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases

Fragoulis, G. E., Dey, M., Zhao, S., Schoones, J., Courvoisier, D., Galloway, J., Hyrich, K. L. and Nikiphorou, E. (2022) Systematic literature review informing the 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. RMD Open, 8(2), e002726. (doi: 10.1136/rmdopen-2022-002726) (PMID:36323488) (PMCID:PMC9639159)

Abstract

Objective: To conduct a systematic literature review (SLR) on the screening and prophylaxis of opportunistic and chronic infections in autoimmune inflammatory rheumatic diseases (AIIRD). Methods: SLR (inception-12/2021) based on the following search domains: (1) infectious agents, (2) AIIRD, (3) immunosuppressives/immunomodulators used in rheumatology, (4) screening terms and (5) prophylaxis terms. Articles were retrieved having the terms from (1) AND (2) AND (3) plus terms from (4) OR(5). Databases searched: PubMed, Embase and Cochrane Library. Exclusion criteria: studies on postoperative infections, paediatric AIIRD, COVID-19, vaccinations and non-Εnglish literature. Study quality was assessed with Newcastle-Ottawa scale for non-randomised controlled trials (RCTs), RoB-Cochrane for RCTs, AMSTAR2 for SLRs. Results: From 5641 studies were retrieved, 568 full-text articles were assessed for eligibility, with 194 articles finally included. For tuberculosis, tuberculin skin test (TST) is affected by treatment with glucocorticoids and conventional synthetic disease modifying anti-rheumatic drugs (DMARDs) and its performance is inferior to interferon gamma release assay (IGRA). Agreement between TST and IGRA is moderate to low. For hepatitis B virus (HBV): risk of reactivation is increased in patients positive for hepatitis B surface antigen. Anti-HBcore positive patients are at low risk for reactivation but should be monitored periodically with liver function tests and/or HBV-viral load. Risk for Hepatitis C reactivation is existing but low in patients treated with biological DMARDs. For Pneumocystis jirovecii, prophylaxis treatment should be considered in patients treated with prednisolone ≥15–30 mg/day for >2–4 weeks. Conclusions: Different screening and prophylaxis approaches are described in the literature, partly determined by individual patient and disease characteristics.

• Item Type: Articles
• Keywords: Hepatitis B virus, COVID-19 - diagnosis - prevention & control, antirheumatic agents, adult, rheumatic diseases - complications - drug therapy, autoimmune diseases, opportunistic infections - diagnosis - etiology - prevention & control, humans, therapeutics, child, antirheumatic agents - adverse effects.
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Fragkoulis, Dr Georgios
• Authors: Fragoulis, G. E., Dey, M., Zhao, S., Schoones, J., Courvoisier, D., Galloway, J., Hyrich, K. L., and Nikiphorou, E.
• College/School: College of Medical Veterinary and Life Sciences > School of Infection & Immunity
• Journal Name: RMD Open
• Publisher: BMJ Publishing Group
• ISSN: 2056-5933
• ISSN (Online): 2056-5933
• Published Online: 02 November 2022
• Copyright Holders: Copyright © 2022 The Authors
• First Published: First published in RMD Open 8(2): e002726
• Publisher Policy: Reproduced under a Creative Commons License